Contact a Trial Coordinator for more information on our trials.
A Multi-Center Open-label Investigation to Assess the Safety and Efficacy of Multiple Doses of DM199 in Patients With Chronic Kidney Disease
December 17, 2019
March 16, 2022
This is an open-label, Phase II, multi-center study evaluating DM199 in approximately 90 Participants in three cohorts.
Cohort I: African Americans with CKD (Stage II or III), hypertension and non-diabetic Cohort II: Participants with IgA nephropathy diagnosis and CKD (Stage II or III) Cohort III: Diabetes Mellitus (Type II) with CKD (Stage II or III) and hypertension.
Participants in each cohort will be enrolled in a parallel assignment to one of two doses:
March 16, 2022
DiaMedica Therapeutics Inc
Male & Female
18 years and older
The following cities have DM199 clinical trial sites. Please check back often as locations will be updated.
For more information on enrollment into our current clinical trial, please contact us or visit clinicaltrials.gov for location information.
A Clinical Trial is a research study in which people volunteer to help find answers to specific health questions. When carefully conducted, they are the safest and fastest way to find new treatments and ways to improve health.
REDUX is being conducted for many reasons:
This clinical trial has certain criteria that a person has to meet to determine if they can participate. The Eligibility criteria are listed above and contain both inclusion and exclusion requirements. After you have discussed the trial with your doctor, contact DiaMedica to coordinate with the study site closest to where you live.
DiaMedica Therapeutics Inc. is sponsoring this clinical trial.
There will be a total of approximately 90 patients enrolled in this clinical trial.
Have your physician complete the contact form.
The safety and efficacy of the investigational use of this product has not been determined. There is no guarantee that the investigational use listed will be filed with and/or approved for marketing by a regulatory agency.